Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Diggs, Laurence P., Hsueh, Eddy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/
https://www.ncbi.nlm.nih.gov/pubmed/28331612
http://dx.doi.org/10.1186/s40364-017-0093-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/
https://www.ncbi.nlm.nih.gov/pubmed/28331612
http://dx.doi.org/10.1186/s40364-017-0093-8

Ejemplares similares